oncolytic virus Archives - ELIAS Animal Health

Oncolytic Virotherapy in Veterinary Medicine

ELIAS Animal Health previously announced it has in-licensed an oncolytic vaccinia virus treatment for pet animals from Genelux Corporation. The agreement grants ELIAS the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine. Check out some of the most frequently asked questions about this agreement and what we plan to do with the technology. What is V-VET1? V-VET1 is Genelux Corporation’s clinical-stage animal health product candidate. It is a vaccinia viral strain that selectively replicates in cancer cells to ultimately cause cell death (apoptosis). Who is Genelux Corporation? Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for human patients suffering from aggressive and/or difficult-to-treat solid tumor types. Learn more about Genelux and their technology at www.genelux.com. What is an oncolytic virus? An oncolytic virus is a virus that can infect and kill cancer [...]

By Jessica Wiley|2023-10-13T13:18:07-06:00October 13th, 2023|Categories: Blog|Tags: clinical trial, oncolytic virus, translational medicine|0 Comments

Canine Cancer Continuum | Part 2: The Connection Between Canine and Human Cancer

We’re halfway through a series exploring canine cancer. Last week, we discussed the prevalence of dog cancer, and today we will explore the connection between it and human cancer. Human cancer research is extensive. Almost anyone I encounter has either battled cancer themselves or has journeyed that path with someone close to them. Many people are surprised to learn that one in four dogs are diagnosed with cancer and that it’s the leading cause of death in canines. ELIAS Animal Health applies the advancements in human immunotherapy to dogs. They’re good models. From a scientific perspective, we are able to gather data more quickly than in human research because dogs have a shorter lifespan and cancer progresses more quickly in them. From a “we love our furry friends” perspective, we want to bring needed therapies into the veterinary marketplace that help people. ELIAS Cancer Therapies Are Being Simultaneously Developed for Humans [...]

By Tammie Wahaus|2023-01-24T19:57:18-06:00January 27th, 2022|Categories: Blog|Tags: cancer immunotherapy, canine cancer, oncolytic virus|0 Comments

ELIAS Animal Health In-Licenses Oncolytic Vaccinia Virus Treatment for Pet Animals from Genelux Corporation

Agreement grants ELIAS Animal Health the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine Nov. 18, 2021 -- Genelux Corporation, a clinical-stage immunotherapy company, recently announced a licensing agreement with ELIAS Animal Health for V-VET1, its clinical-stage animal health product candidate. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis). ELIAS Animal Health is planning clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. “We are thrilled to announce our exclusive license for V-VET1 to help veterinarians treat the many pets who are diagnosed with cancer every year,” said Tammie Wahaus, CEO of ELIAS Animal Health. “Companion animal cancer treatments have made little progress in the past few decades, and this partnership is an exciting step in broadening the cancer treatment options available in veterinary medicine.” [...]

By Jessica Wiley|2022-01-08T14:32:44-06:00November 18th, 2021|Categories: News|Tags: cancer immunotherapy, genelux corporation, oncolytic virus|0 Comments